Abstract
Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 229-235 |
| Number of pages | 7 |
| Journal | Urologic Clinics of North America |
| Volume | 41 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- Guidelines
- Prostate cancer
- Prostate specific antigen (PSA)
- Public health
- Screening
ASJC Scopus subject areas
- Urology
Cite this
Evolution and immediate future of US screening guidelines. / Greene, Kirsten L.; Punnen, Sanoj; Carroll, Peter R.
In: Urologic Clinics of North America, Vol. 41, No. 2, 2014, p. 229-235.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evolution and immediate future of US screening guidelines
AU - Greene, Kirsten L.
AU - Punnen, Sanoj
AU - Carroll, Peter R.
PY - 2014
Y1 - 2014
N2 - Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.
AB - Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.
KW - Guidelines
KW - Prostate cancer
KW - Prostate specific antigen (PSA)
KW - Public health
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=84898029953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898029953&partnerID=8YFLogxK
U2 - 10.1016/j.ucl.2014.01.005
DO - 10.1016/j.ucl.2014.01.005
M3 - Article
C2 - 24725485
AN - SCOPUS:84898029953
VL - 41
SP - 229
EP - 235
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
SN - 0094-0143
IS - 2
ER -